Research programme: T cell therapies - Leveragen/Moonlight Bio
Latest Information Update: 26 Feb 2025
At a glance
- Originator Leveragen; Moonlight Bio
- Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Solid tumours